Introduction
The revival of the cancer immunosurveillance theory (Dunn et al., 2002) has emphasized the role of escape mechanisms in tumor growth Ferrone, 2006, 2007; Kim et al., 2007) . As a result, tumor immunologists have been focusing their investigations on the identification and molecular characterization of the mechanisms by which tumor cells evade immune recognition and destruction Chang et al., 2005; Ferrone, 2006, 2007; Kim et al., 2007) . Among the many escape mechanisms identified, alterations in classical and nonclassical HLA class I as well as HLA class II antigen expression by tumor cells are of particular interest to tumor immunologists and clinical oncologists because of the critical role they play in the generation of tumor antigen (TA)-specific immune responses (Ostrand-Rosenberg, 2004; Knutson and Disis, 2005; Marsman et al., 2005; Moretta et al., 2005) , as well as their ability to modulate the interactions of natural killer (NK) cells (Moretta et al., 2005) and T-cell subpopulations (Ostrand-Rosenberg, 2004; Knutson and Disis, 2005; Marsman et al., 2005; Moretta et al., 2005) with target cells. The potential clinical relevance of these escape mechanisms is suggested by the statistically significant association of changes in classical HLA class I antigen expression (Chang et al., 2005) , as well as of induction of nonclassical HLA class I (Ye et al., 2007; Yie et al., 2007a, b) or of HLA class II antigen (Campoli et al., 2004; Campoli and Ferrone, 2006) expression with the clinical course of the disease in certain malignancies.
As reviewed by (Chang et al., 2005) and shown in Figure 1 , the molecular mechanisms underlying changes in HLA antigen expression in malignant cells include structural gene abnormalities as well as defective regulation of HLA gene transcription and translation. More recently, epigenetic events associated with tumor development and progression have been shown to impair the recognition of tumor cells by components of the adaptive immune system Esteller, 2006; Tomasi et al., 2006; Lettini et al., 2007; Setiadi et al., 2007) . In this regard, epigenetic alterations play a critical role in modifying HLA antigen Khan et al., 2004; Chang et al., 2005; Chou et al., 2005) , antigen processing machinery (APM) component (Chang et al., 2005; Tomasi et al., 2006; Setiadi et al., 2007) , costimulatory molecule Singh et al., 2003; Khan et al., 2004) and TA (Scanlan et al., 2002; Maio et al., 2003; Germenis and Karanikas, 2007) expression in malignant cells. This finding is not surprising as, compared with normal cells, the constitutive patterns of DNA methylation in almost all solid and hematopoietic human malignancies demonstrate global hypomethylation with concomitant, localized hypermethylation (Esteller, 2006; Lettini et al., 2007) . It is noteworthy that, unlike genetic alterations, epigenetic modifications can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. As a result, functional HLA antigen expression and recognition of malignant cells by components of the adaptive immune system can be increased Esteller, 2006; Tomasi et al., 2006; Lettini et al., 2007; Setiadi et al., 2007) . Therefore, studies focused at defining the molecular mechanisms underlying epigenetic modifications of HLA antigen expression may provide us with improved strategies for the treatment of patients with malignant disease.
In this review, we will first succinctly review the types of epigenetic modifications that may occur in normal and malignant cells. Interested readers are referred to more in-depth reviews on this topic (Esteller, 2006; Lettini et al., 2007) . Second, we will summarize the available information about the frequency of classical and nonclassical HLA class I and class II antigen expression in malignant lesions. Third, we will discuss the role of epigenetic modifications underlying changes in HLA antigen expression by malignant cells. It is noteworthy that epigenetic alterations also play a significant role in the deregulation of TA expression Figure 1 Molecular mechanisms underlying the abnormal HLA class I antigen phenotypes identified in malignant cells. Intracellular protein antigens, which are mostly endogenous, are marked for ubiquitination within the cytosol and subsequently degraded into peptides by proteasomal cleavage. Once generated, peptides are transported into the endoplasmic reticulum through the dimeric transporter associated with antigen processing, TAP1 and TAP2. Nascent, HLA class I heavy chains are synthesized in the endoplasmic reticulum (ER) and associate with the chaperone immunoglobulin heavy-chain binding protein (BiP), a universal ER chaperone involved in the translation and insertion of proteins into the ER. Following insertion into the ER, the HLA class I heavy chain associates with antigen processing machinery components (APM), that is, calnexin, ERp57, calreticulin and tapasin. The trimeric HLA class I-b 2 m peptide complex is then transported to the plasma membrane where it plays a major role in the interactions between target cells and T cells. (a) Total HLA class I (HLA-A, -B and -C) loss is caused by loss of b 2 m expression and/or function; (b) Selective HLA class I allospecificity loss is caused by loss of the gene(s), which encode(s) the lost HLA class I allele(s) or by mutations, which inhibit their transcription or translation; (c) total loss of one HLA class I haplotype is caused by total or partial loss of one copy of chromosome 6, which encodes the genes for HLA class I heavy chains; (d) total HLA class I downregulation is caused by loss or downregulation of APM components; (e) selective HLA class I locus downregulation may be caused by locus-specific defects in HLA class I gene transcription. and thereby functional HLA class I and class II antigen peptide complex expression (Lettini et al., 2007) . The latter changes are also likely to play a significant role in the escape of tumor cells from immune recognition and destruction. Interested readers are referred to more indepth reviews on this topic (Scanlan et al., 2002; Maio et al., 2003; Germenis and Karanikas, 2007) . Fourth, we will address the functional relevance and potential clinical significance of abnormalities in HLA antigen expression by malignant cells. Lastly, we will discuss strategies to overcome epigenetic modifications underlying changes in HLA antigen expression in malignant cells.
Epigenetic modifications in normal and malignant cells
Epigenetics refers to changes in gene expression that cannot be accounted for by the changes in primary DNA coding sequence (Esteller, 2006; Lettini et al., 2007) . As summarized in Figure 2 , epigenetic regulation of gene expression includes both transcriptional (Esteller, 2006; Lettini et al., 2007) and post-transcriptional (Esteller, 2006; Lettini et al., 2007) mechanisms. These mechanisms, which have been mostly characterized in cell lines, have been documented also in normal tissues as well as in malignant lesions.
One of the primary epigenetic modifications of the human genome is methylation of cytosine residues within the context of the CpG (cytosine and guanine separated by a phosphate) dinucleotides (Esteller, 2006; Lettini et al., 2007) . Generalized DNA hypomethylation, gene-specific DNA hypomethylation, that is, glioma pathogenesis-related 1 genes such as nuclear factor of activated T-cell 1 and N-acetyltransferase 1, as well as tumor-suppressor gene hypermethylation, that is, RAS, p16 (INK4a), fragile histidine triad, hMLH1 and hMSH2, may be involved in the development and progression of malignant lesions (Fuks et al., 2001; Di Croce et al., 2002; Herman and Baylin, 2003; Esteller, 2006; Lettini et al., 2007) . In this regard, malignant cells display global loss of 5-methylcytosine content (affecting primarily repetitive elements and pericentromeric DNA), which has been linked to the generation of chromosomal instability (Feinberg and Tycko, 2004; Lettini et al., 2007) . On the other hand, malignant cells also demonstrate concomitant gains in methylation of promoter-associated CpG islands with silencing of the associated genes, including tumor-suppressor genes, such as p16
INK4a BRCA1 or hMLH (Jones and Baylin, 2002; Lettini et al., 2007) . The profiles of CpG island hypermethylation of tumor-suppressor genes, which are maintained in established human cancer cell lines, have been shown to vary according to the tumor type (Lettini et al., 2007) . Aberrant hypermethylation of CpG islands, Figure 2 Epigenetic modulations underlying abnormal gene expression identified in malignant cells. In the nucleus, the DNA double helix is wrapped around histone octamers to form nucleosomes, the basic structure of DNA inside the nucleus. (a) Modification of histones through methylation (ÀCH 3 ) or acetlylation (ÀOCCH 3 ) affects gene expression by targeting various protein complexes to DNA, resulting either in an open chromatin structure ready for expression or in a closed chromatin configuration that is impermeable to transcription factors and associated with gene silencing. (b) DNA methylation refers to the enzymatic addition of a methyl group to position 5 of cytosine incorporated into DNA. In mammals, methylation is largely limited to cytosines that are part of the symmetrical dinucleotide CpG (cytosine and guanine separated by a phosphate). A switch from unmethylated to methylated CpG island results in permanent loss of gene expression. (c) RNA interference (RNAi) is a post-transcriptional mechanism whereby gene expression is suppressed by RNA degradation, triggered by short stretches of complementary RNA. This process is a prominent mechanism of epigenetic regulation in plants and other organisms, where it plays roles varying from genome defense to chromosomal structure. associated with transcriptional silencing of selected genes, can affect multiple cellular functions, including cell growth and differentiation, cell-cycle control, and DNA repair as well as angiogenesis, cell adhesion, invasion and apoptosis (Fuks et al., 2001; Di Croce et al., 2002; Jones and Baylin, 2002; Herman and Baylin, 2003; Feinberg and Tycko, 2004; Esteller, 2006; Lettini et al., 2007) . It should be noted that the enzymes that catalyse DNA methylation, that is, DNA methyltransferases (DNMTs), also interact directly with histone de-acetylases (HDAC) (Fuks et al., 2001 ) and can be recruited by gene-specific transcriptional repressors to promoters to silence transcription (Di Croce et al., 2002) .
Histones also play a large part in the control of gene expression and chromatin structure and closely interact with the DNA methylation machinery. Epigenetic modifications of histones, either through targeting by acetylation (Jones and Baylin, 2002; deRuijten et al., 2003; Shogren-Knaak et al., 2006) or DNA methylation (Lachner et al., 2003; Sims et al., 2003; Chuikov et al., 2004; Bedford and Richard, 2005; Esteller, 2006; Lettini et al., 2007) participate in tumor-suppressor gene silencing, either in conjunction or without CpG island hypermethylation. As an example, hypoacetylation of histones, which is frequently associated with CpG island hypermethylation, results in a compact structure of chromatin and represses gene transcription (Esteller, 2006; Lettini et al., 2007) . Furthermore, recent studies have demonstrated that human tumors display an overall loss of monoacetylation of lysine 16 and trimethylation of lysine 20 in the tail of histone H4 (Fraga and Esteller, 2005) . These unique histone modifications have been considered as almost universal epigenetic markers of malignant transformation (Fraga and Esteller, 2005) . Furthermore, modifications can occur on both histone tails and on core histone residues and changes on one histone can require a modification on another histone. These histone modifications affect the interactions between individual histone proteins and ultimately alter the structure of chromatin and thereby gene transcription. It is noteworthy that all the epigenetic alterations currently recognized on histones are reversible and separate sets of unique enzymes responsible for reversing these alterations, that is, acetylases, de-acetylases, methylases and de-methylases, have been identified. It is the balance between the opposing activities of enzymes that add and remove each of the epigenetic marks that determine local changes in chromatin structure at the gene level and gene expression patterns.
An additional type of epigenetic modification that occurs in malignant cells involves the interaction of small, 20-22 nucleotide, noncoding RNA transcripts (ncRNA) which target messenger RNAs (mRNAs) (Berezikov et al., 2005; Sontheimer and Carthew, 2005; Esteller, 2006; Lettini et al., 2007) . This interaction results in the post-transcriptional regulation of mRNA translation and thereby protein expression (Esteller, 2006; Lettini et al., 2007) . Moreover, targeting of nuclear RNA transcriptional complexes by ncRNA promotes histone methylation and may mediate DNA methylation in addition to chromatin silencing (Grewal and Moazed, 2003; Kawasaki and Taira, 2004; Wassenegger, 2005) . ncRNAs, which are typically excised from larger RNA precursors, are involved in crucial biological processes such as development, differentiation, proliferation and apoptosis (Berezikov et al., 2005; Sontheimer and Carthew, 2005; Esteller, 2006; Lettini et al., 2007) . Alterations in the level of ncRNA expression have been detected in many types of human tumors (Calin et al., 2004; Chan et al., 2005; Esteller, 2006; Lettini et al., 2007) . ncRNAs have been proposed to contribute to tumor development and progression because they can function as tumor promoters. In this regard, in human tumors, specific ncRNAs are preferentially located at fragile sites that are common breakpoint regions involved in malignant transformation (Calin et al., 2004; Chan et al., 2005; Esteller, 2006; Lettini et al., 2007) . Moreover, chronic B-cell leukemia has been shown to have a distinct signature of ncRNAs suggesting that ncRNA may be involved in the pathogenesis of this malignant disease (Calin et al., 2004) . The activity of ncRNA can be influenced by chromosomal rearrangements, genomic amplifications or deletions as well as mutations in coding DNA. At present, the mechanism(s) that underlie(s) changes in the function of ncRNAs in malignant cells appears to be related to aberrant gene expression, characterized by abnormal ncRNA expression compared with the corresponding normal tissues. To the best of our knowledge, this mechanism has not been investigated yet as a potential cause of changes in HLA antigen expression in malignant cells. However, the role of ncRNA in the modulation of HLA antigen expression is suggested by the recently described modulation of the NK cellactivating ligand human major histocompatibility complex class I chain-related gene A (MICA) in malignant cells (Friese et al., 2004) .
HLA antigen expression in malignant lesions
Beginning in the 1908's, a large number of malignant lesions have been tested with classical HLA class I and II antigen-specific monoclonal antibodies (mAb; Campoli et al., 2004; Chang et al., 2005; Campoli and Ferrone, 2006) . More recently, these studies have been extended to the analysis of the expression of the nonclassical HLA class I antigens, such as HLA-G Duncker et al., 2007; Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Rouas-Freiss et al., 2007; Sebti et al., 2007; Sheu and Shih, 2007; Wischhusen et al., 2007; Ye et al., 2007; Yie et al., 2007a, b) , as evidence accumulated during the last few years has convincingly shown that these molecules may provide tumor cells with escape mechanisms Duncker et al., 2007; Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Rouas-Freiss et al., 2007; Sebti et al., 2007; Sheu and Shih, 2007 Nevertheless, the available information regarding nonclassical HLA class I antigen expression is still limited, as the field is in an early stage. Furthermore, progress in this area is hindered by the lack and/or limited availability of nonclassical HLA class I antigen-specific mAb, which are suitable for immunohistochemical (IHC) studies.
As reviewed elsewhere (Chang et al., 2005) , with the exception of liver carcinoma, leukemia and lymphoma, abnormalities in classical HLA class I antigen expression have been described in all the types of tumors analysed. The frequency of HLA class I antigen loss and/or downregulation has been found to range from 16 to 80% of the lesions tested in the tumors for which more than 100 lesions have been analysed (Figure 3a) . The highest frequency has been found in bladder, breast and prostate carcinoma, and the lowest in renal cell carcinoma (RCC) and in melanoma.
Among the nonclassical HLA class I antigens, HLA-G expression has been studied the most extensively as more than 150 surgically removed lesions have been analysed for HLA-G expression utilizing binding assays with HLA-G-specific antibodies, immunochemical assays, reverse transcription-PCR and IHC assays (Chang (Cabrera et al., 1995; Seliger et al., 2000; Altomonte et al., 2003; Chil et al., 2003; Lee and Geraghty, 2003; Campoli et al., 2004; Bluestone and Tang, 2005; Marsman et al., 2005; Campoli and Ferrone, 2006; Duncker et al., 2007; Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Rouas-Freiss et al., 2007; Sebti et al., 2007; Sheu and Shih, 2007; Wischhusen et al., 2007; Ye et al., 2007; Yie et al., 2007a, b) . BCC, cutaneous basal-cell carcinoma, ESO, esophageal carcinoma; HNSCC, head-and-neck squamous cell carcinoma; MM, malignant melanoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; UM, uveal melanoma. (') Indicates total HLA class I antigen loss and/or downregulation; ( ) indicates selective HLA class I allospecificity loss. Duncker et al., 2007; Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Rouas-Freiss et al., 2007; Sebti et al., 2007; Sheu and Shih, 2007; Wischhusen et al., 2007; Ye et al., 2007; Yie et al., 2007a, b) . Although the results in the literature conflict, there is a general agreement that malignant transformation of cells may be associated with the appearance of HLA-G. In this regard, HLA-G expression has been convincingly demonstrated in glioma, retinoblastoma, carcinomas of the breast, mesothelia, colon, kidney, bladder, endometrium, ovary and cervix as well as in B-cell chronic lymphocytic lymphoma and in non-Hodgkin B-and T-cell lymphomas ( Figure 3b ) Duncker et al., 2007; Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Rouas-Freiss et al., 2007; Sebti et al., 2007; Sheu and Shih, 2007; Wischhusen et al., 2007; Ye et al., 2007; Yie et al., 2007a, b) .
In contrast to HLA-G, less information is available regarding HLA-E and HLA-F expression by malignant cells (Lee and Geraghty, 2003; Chang et al., 2005; Wischhusen et al., 2007) . HLA-E expression has been investigated in a panel of 37 cell lines derived from different types of tumors as well as a limited number of surgically removed malignant lesions (Lee and Geraghty, 2003; Chang et al., 2005; Wischhusen et al., 2007) . All the 37 cell lines express HLA-E mRNA, while only five (13%) of them express HLA-E proteins on the cell surface (Lee and Geraghty, 2003; Chang et al., 2005; Wischhusen et al., 2007) . Three of the latter five cell lines had been derived from leukemia. In surgically removed malignant lesions, HLA-E expression is increased in glioblastoma, carcinomas of colon and ovary, lymphoma and melanoma (Lee and Geraghty, 2003; Chang et al., 2005; Wischhusen et al., 2007) . Analysis of over 30 cell lines derived from transformed normal cells and malignant lesions has demonstrated that HLA-F is primarily localized in the cytoplasm of cells (Lee and Geraghty, 2003) . Only cell lines derived from EpsteinBarr virus (EBV)-transformed lymphoblastoid, monocytic, glioblastoma, liver carcinoma and transitional cell bladder cells have been found to express HLA-F on the cell surface (Lee and Geraghty, 2003) . Recently, we have found that HLA-E and HLA-F are expressed in four and two, respectively, of the eight breast carcinoma cell lines tested (Chang et al., 2005) . In two cell lines, both HLA-E and HLA-F are expressed. Upon interferon (IFN)-g stimulation, both HLA-E and HLA-F expressions were induced or enhanced on seven of the eight cell lines analysed.
To date, a large number of malignant lesions have been tested with HLA class II antigen-specific mAb in IHC reactions (Campoli et al., 2004; Campoli and Ferrone, 2006) . These studies have shown that HLA class II antigens are often upregulated on malignant cells (Campoli et al., 2004; Campoli and Ferrone, 2006) . The most common types of solid tumors for which more than 100 surgically removed primary lesions have been analysed include carcinomas of the head and neck, esophagus, lung (that is, adeno, large cell and squamous), breast, colon, liver, kidney, bladder, ovary and cervix as well as cutaneous and uveal melanoma. The frequency of HLA class II antigen expression has been found to range from 0 to 100% of the various types of tumors stained with mAb recognizing monomorphic determinants shared by HLA-DR, -DQ and -DP antigens (Figure 3c ). RCC demonstrates the highest frequency and cutaneous basal cell, lung (i.e., squamous) and bladder carcinoma demonstrate the lowest frequency (Campoli et al., 2004; Campoli and Ferrone, 2006) . It is noteworthy that in some tumors such as breast (Campoli et al., 2004) , colon (Cabrera et al., 1995; Seliger et al., 2000; Altomonte et al., 2003; Marsman et al., 2005) and cervical (Chil et al., 2003) carcinoma, HLA class II antigen expression is not restricted to cells that have undergone malignant transformation.
Only limited information is available about the selective losses of classical HLA class and class II antigen. Differential HLA-A and -B antigen expression has been observed in head-and-neck squamous cell carcinoma, colorectal carcinoma and melanoma and differential HLA-DR, -DQ and -DP antigen expression has been observed in malignant cells derived from carcinoma of breast (Campoli et al., 2004) , liver and colon (Cabrera et al., 1995; Seliger et al., 2000; Altomonte et al., 2003; Marsman et al., 2005) as well as leukemic cells (Drexler et al., 1988; Lecchi et al., 1989) and primary and metastatic cutaneous melanoma lesions (Ruiter et al., 1991; Campoli and Ferrone, 2006) . The analysis of HLA allospecificity expression has only been performed for HLA class I antigen most likely because of the need of this information to interpret the results of T-cell-based immunotherapy. As observed in total HLA class I antigen defects, the frequency of selective HLA class I antigen abnormalities varies among different types of tumors; it has been found to be higher in primary cervical carcinoma, prostate carcinoma and cutaneous melanoma lesions than in primary head-and-neck squamous cell carcinoma, breast carcinoma, lung carcinoma, RCC and colon carcinoma lesions (Chang et al., 2005) .
Multiple reasons are likely to contribute to the differences in the frequency of HLA antigen changes in various types of tumors. Some of them are technical in nature such as sensitivity of the IHC reaction used, characteristics of the mAb used in the IHC reactions and subjective evaluation of IHC staining. Furthermore, HLA antigen expression in endothelial and/or lymphoid cells present in tissue sections, which is used in the majority of cases as a standard for evaluating the degree of expression of these molecules by malignant cells, does not represent the most appropriate control, when tumor cells being evaluated are of a different lineage.
Among the biologic variables, which generally have not been taken into account in the design and analysis of previous studies, but are likely to influence the expression of HLA antigens are heterogeneity of the patient populations investigated in terms of clinical stage, previous therapy and length of the follow-up periods. The complexity of malignant disease, which is not a single disease entity, can also play a role, as the frequency of HLA antigen expression varies among histologic subtypes of breast, lung, colon and ovarian carcinoma as well as uveal and cutaneous melanoma (Campoli et al., 2004; Chang et al., 2005; Campoli and Ferrone, 2006) . These results emphasize the need to stratify tumors according to their histotype when analysing HLA antigen expression. Moreover, the assessment of the degree of downregulation of HLA antigens on malignant cells suffers from the scant information about their level of expression in normal tissues. Consequently, it is difficult to determine what constitutes a normal or a pathological expression level.
The time length between the onset of tumor and diagnosis, along with the level of exposure to T-cell selective pressure (Chang and Ferrone, 2007) , is also likely to play a role in the variable frequency of HLA expression among the various tumors. In this regard, the lower frequency of classical HLA class I antigen defects in leukemic and lymphoma cells may reflect the time interval between the onset of the disease and the diagnosis. This time is likely to be shorter than that in most solid tumors and thereby results in a decreased level of exposure to T-cell selective pressure. Moreover, because of their hematogeneous route of primary tumor and metastasis formation, leukemic and lymphoma cells are targeted by NK cells, which are often distributed in the peripheral blood as well as in secondary and tertiary lymphoid sites (i.e., lung, liver, spleen, bone marrow and lymph nodes) (Backstro¨m et al., 2004) . The role of NK cells in controlling leukemic cells is supported by the association between a decrease in NK cell function and progression of chronic myelogenous leukemia from chronic phase to blast crisis (Verfaillie et al., 1990; Pierson and Miller, 1996; Chiorean et al., 2003) . Therefore, the high level of HLA class I antigen expression found in leukemia and lymphoma cells may result from the outgrowth of tumor cells with high HLA class I expression because of their reduced susceptibility to NK cell-mediated lysis. This possibility is supported by the selective HLA-A and HLA-Bw6 allospecificity downregulation, which has been found in leukemic cells; this phenotype does not increase the susceptibility of target cells to NK cell-mediated lysis (Demanet et al., 2004) .
In the case of liver carcinoma, normal hepatocytes, which do not express or express very low levels of the transporter associated with antigen processing (TAP), a component of the HLA class I APM, and of classical HLA class I antigen, acquire the expression of these antigens during malignant transformation (Chang et al., 2005) . The lack of defects in classical HLA class I antigen expression identified in liver carcinoma cells may reflect the type of immune selective pressure imposed on tumor cell populations. In this regard, many NK cells reside in the liver (Backstro¨m et al., 2004) . The decrease in their activity in patients with chronic liver diseases and in those with liver carcinoma may reduce the selective growth of malignant hepatocytes with HLA class I antigen defects (Chuang et al., 1990; Ono et al., 1996) . Furthermore, expression of the NK cell-activating ligands MICA/B by liver carcinoma cells has been suggested to play an important role in the susceptibility of liver carcinoma cells to NK cellmediated cytolysis (Jinushi et al., 2003) . Therefore, the acquisition of classical HLA class I antigen expression by liver cells during malignant transformation might reflect the selection of cells, which are resistant to NK cell-mediated lysis.
Epigenetic mechanisms underlying altered HLA expression in malignant cells
During the last few years, epigenetic alterations have been shown to play a role in HLA antigen changes associated with malignant transformation of cells. It is noteworthy that the epigenetic alterations, which will be reviewed in the next few sections, have mostly been documented in cell lines derived from malignant lesions. Therefore, the in vivo relevance of these data remains to be assessed.
Classical HLA class I antigens
The notion that epigenetic alterations modulate HLA antigen changes in malignant cells was first suggested by studies showing that HLA antigen expression can be recovered by treatment with DNA methylation and HDAC inhibitors Khan et al., 2004; Chang et al., 2005; Chou et al., 2005) . More recently, hypermethylation of the IFN-regulatory factor 1 gene has been found to bring about inhibition of IFNg-mediated HLA class I expression in two melanoma cell lines (Rodrı´guez et al., 2007) . In addition, hypermethylation of the HLA-A, B and C gene promoter regions and/or altered chromatin structure of the HLA class I heavy chain gene promoters have been implicated as a major mechanism for transcriptional inactivation of HLA class I genes in esophageal squamous cell carcinoma lesions (Nie et al., 2001 ) and for total HLA class I antigen downregulation in cutaneous primary and metastatic melanoma lesions (Serrano et al., 2001; Fonsatti et al., 2003) . It is noteworthy that epigenetic alterations do not have to be restricted to genes encoding HLA class I heavy chains to affect the expression of these antigens. One mechanism, which causes lack of HLA class I antigen cell surface expression is represented by post-transcriptional regulation of b 2 m, a critical component of the HLA class I heavy chain-b 2 m peptide complex, which has been described in a drug-resistant breast carcinoma cell line (Ogretmen et al., 1998) . Moreover, changes in HLA class I antigen expression may also reflect alterations in transcriptional regulation of the APM components. The latter play a critical role in the assembly and presentation of functional HLA class I antigens (Chang et al., 2005; Tomasi et al., 2006; Setiadi et al., 2007) . In this regard, with the exception of some rare examples of TAP1, tapasin and low molecular mass polypeptide (LMP) subunit mutations found in some small cell lung carcinoma, cervical carcinoma, neuroblastoma and cutaneous melanoma cell lines, structural alterations in APM component genes appear to be a rare event (Khan et al., 2008; Seliger, 2008) . On the basis of the low frequency of sequence abnormalities, it has been suggested that APM components are mainly regulated at the epigenetic, transcriptional and/or post-transcriptional level in human tumors. The latter is supported by the markedly heterogeneous APM component promoter activities detected in a number of human tumor cell lines of different histotype suggesting a transcriptional regulation of APM component expression (Seliger, 2008) . Methylation of the taspasin and/or TAP2 promoter has been demonstrated in melanoma and RCC cell lines and treatment with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5-AC) results in the enhancement and/or reconstitution of not only tapasin and TAP2 but also TAP1 transcription and translation (Seliger, 2008) . In addition, treatment of some esophageal squamous cell carcinoma, colon carcinoma, RCC and melanoma cell lines with the DNA demethylating agent 5-AC and/or HDAC results in the induction of APM component transcription and translation (Khan et al., 2008; Seliger, 2008) . Along the same lines, hypoacetylation of the H3 histone leads to deficient TAP-1 expression, a critical APM component, and ultimately reduced HLA class I expression in a lung carcinoma cell line (Setiadi et al., 2007) . Similar studies have also demonstrated that specific APM components, including LMP7, TAP1, TAP2 and tapasin, can be epigenetically regulated in murine tumors (Tomasi et al., 2006) . It is noteworthy that HDAC inhibitors also enhance the expression of classical major histocompatability classes (MHCs) I and II as well as the costimulatory molecule CD40 in mouse tumor cells, suggesting that epigenetic mechanisms play a role across species . Whether these findings reflect direct epigenetic control of APM component expression and/or indirect control through yet to be defined transcription factors remains to be determined.
Nonclassical HLA class I antigens
In attempts to resolve the issue of the aforementioned conflicting results regarding HLA-G expression between in vivo and in vitro conditions (Chang et al., 2005) , the mechanism(s) by which HLA-G expression is modulated in malignant cells has(have) been investigated. A number of studies have demonstrated that stress proteins as well as cytokines such as granulocyte monocyte colony stimulating factor (GM-CSF), IFNs, interleukin (IL)-10 and leukemia inhibitory factor (LIF) upregulate HLA-G protein expression by tumor cells Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Ye et al., 2007; Yie et al., 2007a) . However, cytokines have no effect on the induction of HLA-G gene transcription in tumor cells in which the HLA-G gene is repressed. In this context, epigenetic mechanisms such as DNA methylation and histone hypoacetylation have been found to underlie repression of HLA-G gene expression (Chang et Ye et al., 2007; Yie et al., 2007a) . Specifically, in all tumor cell lines tested, the HDAC inhibitor trichostatin A and the DNA demethylating agent 5-AC can induce HLA-G gene transcription, and in some cases translation, that is, increased intracellular and cell surface HLA-G expression. These results are not limited to the human systems but have also been described in mouse cells Lin et al., 2007; Morandi et al., 2007; Pistoia et al., 2007; Ye et al., 2007; Yie et al., 2007a) . It should be noted that only a limited number of tumor cell lines have been examined thus far for HLA-G expression after exposure to trichostatin A and/or 5-AC. Thus, whether HLA-G induction by 5-AC represents a general rule in tumor cells remains to be determined. Furthermore, it is not known whether demethylation of the HLA-G promoter is the cause for HLA-G induction in tumor cells in vitro, because the methylation status of the HLA-G promoter before and after 5-AC treatment has not been examined and 5-AC can modulate the expression of genes utilizing mechanisms different from demethylation. Lastly, it is not known whether the role of in vitro promoter hypomethylation in HLA-G induction in tumor cells has an in vivo counterpart. If the in vitro findings are not paralleled by in vivo data, it is tempting to speculate that the HLA-G promoter becomes methylated in tumor cells following adaptation to tissue culture. This possibility is supported by the methylation of multiple gene promoters, including MyoD1, a-globin, MHC I and triophosphate isomerase when cells are adapted to tissue culture (Tomasi et al., 2006) . It is worth noting that 5-AC causes DNA damage, which may act as a stress factor to induce HLA-G expression in tumor cells. Clearly, additional experiments are required to determine the role of HLA-G promoter hypomethylation in the induction of HLA-G expression by tumor cells.
HLA class II antigens
The genes encoding HLA class II antigens, that is, HLA-DR, -DQ, and -DP, as well as those encoding the accessory molecules involved in HLA class II antigen presentation, that is, the invariant chain (Ii) and HLA-DM, are coordinately regulated. Their expression, at the transcriptional level, is primarily controlled by the class II transactivator protein (CIITA) (Creswell, 2005; Marsman et al., 2005; Wright and Ting, 2006b) . Four promoters regulate different isoforms of CIITA expression in a cell-specific manner (Creswell, 2005; Marsman et al., 2005; Wright and Ting, 2006b ). Constitutive CIITA expression in dendritic cells is controlled by promoter I (D-CIITA), while CIITA expression in Blymphocytes is driven by promoter III (B-CIITA) (Creswell, 2005) . Not surprisingly, epigenetic mechanisms have also been found to underlie defects in HLA class II antigen expression in malignant cells. Both hypermethylation of the CIITA promoter IV (Reith et al., 2005; Wright and Ting, 2006a) et al., 2000) . The above mechanism has been documented in cell lines derived from carcinoma of breast (Campoli et al., 2004) , stomach (van der Stoep et al., 2002; Satoh et al., 2004) , colon Chou et al., 2005) , cervix (Wright and Ting, 2006a) , cutaneous epithelia (Kanaseki et al., 2003) as well as from T-cell leukemia , neuroblastoma (Takamura et al., 2004) , teratocarcinoma (Tomasi et al., 2006) , choriocarcinoma (Tomasi et al., 2006) and uveal and cutaneous melanoma (Campoli and Ferrone, 2006) . More recent studies have suggested that Blimp-1, a zincfinger DNA-binding protein, recruits a corepressor complex containing HDAC to the CIITA promoter and this may be responsible for the failure of the plasma cells and related tumors to express HLA class II antigen (Yu et al., 2000) . HDAC inhibitors can induce CIITA expression and enhance HLA class II antigen expression on plasma cell tumors (Ghosh et al., 2001) . It should be noted that in several human malignant cell lines and in normal mouse kidney epithelial cell cultures, HDAC inhibitors can induce HLA class II antigen expression through an apparent CIITA-independent pathway (Chou et al., 2005) .
Functional relevance of changes in classical and nonclassical HLA class I antigen and HLA class II antigen expression in malignant cells
Convincing evidence indicates that to evade the host's immune response, tumor cells may utilize multiple escape mechanisms. In this regard, tumor cells may exploit, in addition to structural mutations, epigenetic repression of genes encoding HLA antigens and accessory molecules to evade immune recognition and destruction (Figure 4) . In this section, we discuss how changes in HLA antigen expression in tumor cells may provide them with escape mechanisms.
Classical HLA class I antigens
The role of HLA class I antigen in the recognition and destruction of tumor cells by HLA class I antigenrestricted, TA-specific cytotoxic T-lymphocytes (CTLs) implies that the defects in HLA class I antigen expression in malignant lesions may have a negative impact on the clinical course of malignant diseases if the latter is influenced by a TA-specific CTL-mediated immune response. Furthermore, defects in HLA class I antigen expression in malignant lesions are expected to counteract the potential beneficial effects of T cell-based immunotherapy, as they may provide tumor cells with a mechanism to evade CTL recognition. It is likely that the interplay of genetic and epigenetic modifications in tumor cells influences not only the developmental processes of carcinogenesis but also selective pressures involved in immune escape. The potential involvement of immune selective pressure in these events is suggested by several lines of clinical and experimental evidence, all of which have in common the possibility that tumor cells with genetic and/or epigenetic defects in HLA class I antigen may be out-selected by T cell-mediated selective pressure present in the tumor microenvironment (Johnsen et al., 1999; Lozupone et al., 2003; Chang et al., 2005; Chang and Ferrone, 2007) . This notion is supported by the association of HLA class I antigen downregulation with a reduction in disease-free interval and survival in head-and-neck squamous cell carcinoma, breast carcinoma, small cell lung carcinoma, bladder carcinoma, cervical carcinoma and cutaneous melanoma (Chang et al., 2005) . Furthermore, in prostate carcinoma, when the degree of tumor differentiation is taken into account, the disease-free interval and survival of patients with prostate carcinoma, whose lesions demonstrate HLA class I antigen abnormalities, is shorter than those of patients whose lesions have a similar degree of tumor differentiation and do not demonstrate detectable HLA class I antigen abnormalities (Chang et al., 2005) . These clinical findings have been suggested to reflect resistance of malignant cells to lysis by CTL through lack of TA-derived peptides presented properly in the context of a HLA class I allospecificity. The lack of HLA class I antigen-TA peptide complex expression may also account for the association of TAP1, a critical APM component, downregulation with tumor grading, tumor staging and reduction in patients' survival in breast carcinoma, SCLC, cervical cancer and cutaneous melanoma (Chang et al., 2005) . In this regard, alterations in TAP1 expression lead to defective peptide loading of HLA class I antigens and their ultimate expression on the cell surface. Interestingly, TAP1 expression has been suggested to represent an independent prognostic marker for patients with cutaneous melanoma, as its downregulation in primary lesions has been found to correlate with metastasis development and prognosis better than the traditional prognostic marker, that is, tumor thickness (Chang et al., 2005) . If these findings are confirmed, the analysis of TAP1 expression in primary cutaneous melanoma lesions may represent a useful molecular marker to evaluate melanoma patients' prognosis. Whether this conclusion applies also to other types of malignancies remains to be determined.
Nonclassical HLA class I antigens
Although there is less information regarding the role of nonclassical HLA class I antigen expression by malignant cells in immune escape, the available clinical and experimental evidence suggests, although does not prove, that selective pressure is imposed on tumor cells, which have spontaneously arisen in a host or have been transplanted to a host, not only by CTL but also by NK cells. Thus, the association between poor prognosis and HLA class I antigen loss in malignant lesions described in several malignant diseases (Chang et al., 2005) as well as the increased ability to metastasize of tumor cells with HLA class I antigen (Chang et al., 2005) defects raise the possibility that NK cells cannot control tumor growth, because the tumor cell population has been immunoselected for nonclassical HLA class I antigen expression and/or lack of NK cell-activating ligand expression by NK cell selective pressure. As mentioned above, HLA-G expression has been documented in several different types of malignant lesions and its expression in carcinomas of the lung (Yie et al., 2007b) , stomach (Yie et al., 2007a) and colon (Ye et al., 2007) is associated with poor prognosis. Moreover, elevated soluble HLA-G protein levels have been demonstrated in sera of patients with carcinomas derived from breast and ovarian cells as well as melanoma, glioma and lymphoproliferative disorders (Pistoia et al., 2007; Sheu and Shih, 2007) . The HLA-G serum level was inversely correlated with survival in glioblastoma multiforme (Sheu and Shih, 2007) and was directly correlated with advanced disease stage and with tumor load in melanoma (Sheu and Shih, 2007) . These findings suggest that tumor cell expression of HLA-G expression may represent a mechanism of resistance to NK cellmediated killing. This mechanism may parallel the manner in which HLA-G protects against NK cellmediated rejection of fetal tissues in the placenta (Hunt et al., 2006) . Moreover, HLA-G may provide tumor cells with additional resistance from immune recognition and destruction through their ability to inhibit the cytotoxic activity and/or the proliferative ability of CTL and CD4 þ T-helper cells, respectively, as well as to induce the generation of a new type of regulatory T cells, either CD4 to activated T cells ('trogocytosis') (Wischhusen et al., 2007) . It should be noted that NK cell-mediated killing of tumor cells involves a complex interplay between classical and nonclassical HLA class I antigen as well as NK cell-activating ligands. Therefore, aberrant HLA-G expression may not be required for tumor cell escape in diseases in which NK cells play a major role in controlling tumor growth, since class HLA class I antigens have a strong inhibitory capacity through their interaction with NK inhibitory receptors (Chang and Ferrone, 2006) . Similarly, other nonclassical HLA class I molecules such as HLA-E might also contribute to NK tumor cell escape. It is well documented that HLA-E is widely transcribed in most tissues, and that this molecule is expressed when it combines with the leader peptides of other HLA class I molecules including HLA-G Wischhusen et al., 2007) . It is thought that NK cells, through interaction with the CD94/NKG2A inhibitory receptor, may utilize HLA-E to monitor the level of classical HLA class I antigen expression on target cells Wischhusen et al., 2007) .
HLA class II antigens
Conflicting information is available among different malignant diseases as well as within the same malignant disease regarding the functional and clinical significance of HLA class II antigen expression in malignant lesions (Campoli et al., 2004; Chang et al., 2005; Campoli and Ferrone, 2006) . The results range from association of HLA class II antigen expression with favorable or unfavorable clinical course of the disease to lack of association. The conflicting results are likely to reflect the role of the technical and biological variables that we have previously mentioned to explain the different frequencies of HLA class II expression in malignant lesions. In addition, we believe that the conflicting information regarding the clinical significance of HLA class II antigen expression in malignant cells, is due, in part, to the fact that the analysis has only been restricted to HLA-DR, -DQ, and -DP expression on the cell membrane without taking into consideration other molecules that are likely to greatly affect the functional properties of HLA class II such as HLA class I, APM components and costimulatory molecules. All of these components are required for a cell to efficiently present HLA class II peptide complexes to CD4 þ T cells and the importance of their coordinated expression is highlighted by several in vitro and in vivo observations. In vitro binding of CD4 þ T cells to HLA class II antigens on tumor cells in the absence of costimulatory molecules can lead to an immune-suppressed or anergic state of the CD4 þ T cell (Knutson and Disis, 2005; Whiteside et al., 2005) . Moreover, the clinical relevance of the coexpression of HLA class II antigen and costimulatory molecule as well as HLA class I antigen is indicated by the association of HLA class II antigen expression in cutaneous metastatic melanoma lesions with a favorable prognosis only when it is coexpressed with the costimulatory molecule B7.1 and with HLA class I antigen (Bernsen et al., 2003) . In this regard, it should be noted that epigenetic regulation of costimulatory molecules has been reported in several human and murine malignant cell lines, and surface expression of CD40 and B7-1/2 costimulatory molecules can be induced by treatment with HDAC inhibitors .
The role of HLA class II APM component expression in the clinical course of the disease is underscored by at least three lines of evidence. First, the repertoire of peptides displayed by HLA class II antigens is altered and possibly CD4 þ T-cell anergy is induced when HLA class II antigen-positive malignant cells display low basal levels of a g-IFN-inducible lysosomal thiol reductase, an HLA class II APM component (Creswell, 2005) . Second, in neuroblastoma, IFN-g-induced HLA-DO expression alters the repertoire of peptides presented by HLA class II antigens to CD4 þ T cells and can lead to CD4 þ T-cell anergy (Chamuleau et al., 2006) . Third, overexpression of Ii, is associated with poor clinical course of the disease in patients with gastric (Tamori et al., 2005) and colorectal (Jiang et al., 1999) carcinoma. Whether alterations in other accessory molecules occur in malignant diseases and play a role in their clinical course remains to be determined. Nevertheless, the available information suggests that the analysis of HLA class II antigen expression should be combined with that of other APM components.
In the appropriate setting, malignant cells may act as effective APC for HLA class II antigen-restricted, antigen-specific CD4 þ T cells. Normally, interaction of CD4 þ T cells with HLA class II antigen-peptide complexes and costimulatory molecules expressed on typical APC, leads to (i) the production of a spectrum of cytokines that facilitates the growth and differentiation of CD8 þ T cells and (ii) activation of APC through CD40-CD40L interactions, which leads to enhanced antigen presentation. Optimal induction of CTL benefits from the presence of activated CD4 þ T cell and APC. More recently, CD4 þ T cells have been shown to exert direct HLA class II antigen restricted, antigen-specific cytotoxic effects on malignant cells in vitro through Fasdependent and independent mechanisms, that is, granzyme and perforins (Knutson and Disis, 2005) . Nonetheless, there is only indirect evidence of HLA class II antigen-restricted, TA-specific CD4 þ T-cell killing of HLA class II antigen-bearing tumor cells in vitro. Whether and/or how HLA class II antigen expression by tumor cells plays a role in the activation, maintenance, or effector phase of a TA-specific cellular immune response is not known at present.
HLA class II antigen-restricted, TA-specific CD4 þ T cells may also exert cytotoxic effects on HLA class II antigen-bearing and nonbearing tumor cells through indirect mechanisms. In this regard, the recognition of HLA class II antigen-TA-derived peptide complexes on tumor cells by HLA class II antigen-restricted, antigenspecific CD4 þ T cells may lead to release of cytokines that ultimately results in killing of tumor cells through the activated eosinophils, macrophages and neutrophils as well as type 1 cytokines, that is, IFNs (Knutson and Disis, 2005) . In the latter case, the type 1 cytokine IFN a plays an important role in regulating tumor growth in vivo by both the innate and adaptive immune system as well as by inhibiting tumor bed angiogenesis (Knutson and Disis, 2005) . In contrast to their beneficial role in TA-specific immune responses, HLA class II antigen expressed by tumor cells may have a negative impact on the immune response through their interaction with a subpopulation of CD4 þ T cells known as T regulatory (T reg ) cells (Bluestone and Tang, 2005; Chattopadhyay et al., 2005) . Two groups of T reg cells have been identified, natural T reg cells (nT reg ), which are believed to be selected in the thymus as an antiself repertoire, and induced T reg cells (iT reg ), which are believed to be induced in the periphery. Both play a major role in maintaining self-tolerance by regulating immune responses (Bluestone and Tang, 2005; Chattopadhyay et al., 2005) . While nT reg cells require TCR ligands and costimulation for functional activation, iT reg cells need only TCR ligands (Bluestone and Tang, 2005; Chattopadhyay et al., 2005) . Once activated, both nT reg and iT reg are powerful nonspecific suppressors of TA-specific immunity by inhibiting IL-2 transcription in target CD4 þ T and NK T cells, thereby preventing expansion of effector and helper T-cell populations (Bluestone and Tang, 2005; Chattopadhyay et al., 2005) . HLA class II antigen expression by malignant cells may, therefore, lead to T reg -cell activation and possibly to the downregulation of an ongoing TA-specific immune response through the secretion of immunosuppressive cytokines like IL-10 or TGF-b in a contact-independent manner or through a contact-dependent manner through CTLA-4 (Bluestone and Tang, 2005; Chattopadhyay et al., 2005) .
Immune escape and epigenetic therapeutics
The lack of effective treatment for advanced stage malignant disease has highlighted the need to develop alternative therapeutic strategies. Among them, immunotherapy has attracted much attention because of the potential role played by immunological events in the clinical course of malignant disease (Wang et al., 2005) . In view of the well-recognized immune escape mechanisms utilized by malignant cells (Kim et al., 2007) as well as their genetic instability, the disappointing clinical response rates, observed in a majority of the activespecific immunotherapy trials conducted to date (Wang et al., 2005) , are likely to reflect the ability of malignant cells to escape immune recognition and destruction and/ or their capacity to interfere with the differentiation, function and/or survival of immune effector cells. In the remaining part of this section, we will review several potential strategies that may counteract the multiple epigenetic-based escape mechanisms utilized by tumor cells and provide us with improved strategies for the treatment of patients with malignant disease.
The available evidence we have summarized in a previous section suggests that epigenetic alterations may underlie not only changes in HLA antigen, but also APM component and costimulatory molecule expression in malignant cells. The latter result in the ability of malignant cells with HLA antigen defects to avoid immune recognition and destruction. At variance with structural gene mutations, epigenetic changes can generally be reversed in cells with various pharmacological agents. Therefore, pharmacological modulation of the epigenetic profile of malignant cells, such as histone acetylation/deacetylation, histone methylation and, in particular, DNA methylation, may allow the development of improved approaches toward the implementation of active-specific immunotherapy for patients with malignant disease.
Among the currently available pharmacological agents 5-AC has been shown to be a suitable agent to alter methylation profiles in malignant cells (Esteller, 2003) . At high doses, 5-AC induces apoptotic cell death triggered by the production of DNA adducts and consequent DNA synthesis arrest, whereas at low doses, it is incorporated into DNA and inhibits DNMT leading to global hypomethylation. (Esteller, 2003) , Treatment of malignant cells with 5-AC results not only in the induction of HLA class I and class II antigen expression, each of which are required for an effective TA-specific immune response, but also in the induction of genes involved in the control of apoptosis, proliferation, DNA repair and cellular senescence, that is, p21 waf p16 and p27 and downregulation of cyclin A, cyclin D, CDK4 and dephosphorylation of pRb (Neumeister et al., 2002; Tomasi et al., 2006) . The upregulation of classical MHC class I antigen expression on malignant cells after treatment with 5-AC has been shown to enhance the recognition of tumor cells by CTL in animal models and human malignant cell lines (Sigalotti et al., 2004; Coral et al., 2006 Coral et al., , 2007 Guo et al., 2006; Tomasi et al., 2006; Fonsatti et al., 2007) .
Both 5-AC and its derivatives, that is, decitabine, have been introduced into the clinic with encouraging results in hematopoietic disorders such as myelodysplastic syndrome, acute myeloid leukemia and chronic myelogenous leukemia (Wijermans et al., 2000; Sigalotti et al., 2003; Issa et al., 2004) as well as solid tumors including lung and esophageal cancers (Schrump et al., 2006) . In each case, treatment with decitabine was shown to induce or upregulate CIITA expression in malignant cells. Along this line, recent results of a phase I clinical study of the combined treatment with decitabine plus high-dose IL-2 in melanoma and RCC suggest that decitabine may synergistically act with immunological treatments, that is, IL-2 therapy, resulting in improved clinical response rates (Gollob et al., 2006) . Similar to 5-AC, HDAC inhibitors may be useful in the treatment of malignant diseases. Upregulation of p21 waf p16 and p27 and downregulation of cyclin A, cyclin D, CDK4 and dephosphorylation of pRb, genes necessary for cell-cycle arrest and growth inhibition of tumor cells, are common features of HDAC inhibitor treatment and are due to both direct and indirect mechanisms (Fang et al., 2003; Egger et al., 2004; Li and Wu, 2004) . Moreover, HDAC inhibitor treatment of a broad spectrum of malignant cells including carcinomas of the breast, lung, bladder, ovarian, and prostate as well as leukemias, lymphomas and myelomas results in the concentration-dependent induction of differentiation, growth arrest and apoptosis (Tomasi et al., 2006) . To date, HDAC inhibitors have shown significant antitumor effects in preclinical models and in phase I/II clinical trials for the treatment of carcinomas of the breast, lung and cervix as well as myelodysplastic syndrome, acute myeloid leukemia, chronic lymphocytic lymphoma, glioma and melanoma (Bovenzi et al., 1999; Florenes et al., 2004; Lucas et al., 2004; Moore et al., 2004; Eramo et al., 2005; Insinga et al., 2005; Natoni et al., 2005) . More recently, the HDAC inhibitor Zolinza was approved for use in the treatment of cutaneous T-cell lymphoma (Mann et al., 2007) .
Although the precise molecular pathways involved in the antitumor effects of DNA methylation and HDAC inhibitors have not been fully determined, it is likely that they can be attributed to their ability to modulate genes necessary for cell-cycle arrest and growth inhibition as well as genes involved in tumor immunity. The inhibition of DNA methylation and histone de-acetylation can enhance classical MHC class I and class II antigens, CD40, B7-1/2, as well as ICAM-1 expression in various human and mouse tumor cell lines Tomasi et al., 2006) . Moreover, inhibition of histone de-acetylation in malignant cells can increase the expression of various proapoptotic and death-inducing pathways, such as Fas, DR4 and DR5 expression causing tumors to become sensitive to killing by FasL and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), respectively (French and Tschopp, 2002) . Alternatively, inhibition of histone de-acetylation can down-modulate the antiapoptotic molecule, cellular caspase-8 (FLICE)-like inhibitory protein (cFLIP), in malignant cells rendering them more susceptible to Fasmediated killing by CTL (Bovenzi et al., 1999; Natoni et al., 2005) . This is an important reminder that the modulation of epigenetic processes in tumor cells may silence nearly as many genes as they activate and may thereby reverse specific gene induction critical to tumor growth and/or immune escape.
Despite the promising data arising from clinical trials, there are several pitfalls regarding the clinical application of demethylating agents as well as HDAC inhibitors. The inherent toxicity of nucleoside DNMT inhibitors might be caused by the formation of covalent adducts between DNA and trapped DNMTs, which may be responsible for bone marrow and other host toxicities (French and Tschopp, 2002; Bhalla, 2005; Szyf, 2005) . Furthermore, the majority of the available drugs that inhibit DNA methylation are not specific and result in widespread DNA hypomethylation and the production of unwanted effects such as induction of oncogene expression. However, optimizing treatment schedules might decrease toxicity, for example, giving lower doses over longer time periods, thereby exposing more cells to the drug during the S phase. It should be noted that on additional pitfall of the DNMT inhibitor, decitabine is the increased expression of multidrug resistance 1, a gene whose expression enhances drug resistance and uPA, a prometastatic gene in nonmetastatic breast tumor cells (Szyf, 2005) . Additional compounds that directly inhibit DNMTs and do not need to be incorporated in DNA such as nonnucleoside inhibitors and antisense oligodeoxynucleotides are currently being developed and may lead to lower toxicity (Villar-Garea and Esteller, 2004; Acharya et al., 2005) . In general, HDAC inhibitors given systemically are generally well tolerated but the accumulation of acetylated histones in normal tissues may induce some toxicity depending on the dose, route and specific drug (Villar-Garea and Esteller, 2004; Acharya et al., 2005) .
Conclusion
Malignant cells frequently demonstrate alterations in HLA antigen expression, which are believed to play a major role in their ability to escape immune recognition and destruction. Epigenetic modulations in gene expression are likely to play a large part in the observed alterations in HLA antigen expression by malignant cells, since epigenetic events are involved in the silencing and/or in the downregulation of genes necessary for cellcycle arrest and growth inhibition as well as genes involved in tumor immunity. The ability of epigenetic drugs to restore the defective HLA antigen, APM component and costimulatory molecule expression, and the consequent increase in immune recognition of malignant cells, provides us with new therapeutic tools that may improve the clinical efficacy of T cell based-immunotherapy for the treatment of malignant disease. In this regard, the combination of immunization strategies with approaches that counteract tumor cell-induced immune suppression and tumor immune escape, such as DNMT and HDAC inhibitors, may enhance the clinical efficacy of immunotherapy. Nonetheless, to date, very little attention has been focused on the regulation of HLA antigens in malignant lesions following treatment with DNMT and HDAC inhibitors. Therefore, future studies should be directed at investigating the ability of epigenetic pharmacologic agents to modulate HLA antigen expression in malignant lesions.
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